S. Lheureux, C. Denoyelle, P. S. Ohashi, D. Bono, J. S. Mottaghy et al., Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician, Eur J Nucl Med Mol Imaging, vol.44, pp.41-54, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01856113

B. Merelli, D. Massi, L. Cattaneo, and M. Mandala, Targeting the PD1/ PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities, Crit Rev Oncol Hematol, vol.89, pp.140-65, 2014.

I. Mellman, G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age, Nature, vol.480, pp.480-489, 2011.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, pp.252-64, 2012.

K. Bardhan, T. Anagnostou, and V. A. Boussiotis, The PD1:PD-L1/2 pathway from discovery to clinical implementation, Front Immunol, vol.7, p.550, 2016.

E. I. Buchbinder and A. Desai, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition, Am J Clin Oncol, vol.39, pp.98-106, 2016.

C. Vanpouille-box, S. C. Formenti, and S. Demaria, Toward precision radiotherapy for use with immune checkpoint blockers, Clin Cancer Res, vol.24, pp.259-65, 2018.

S. Cousin and A. Italiano, Molecular pathways: immune checkpoint antibodies and their toxicities, Clin Cancer Res, vol.22, pp.4550-4555, 2016.

L. Khoja, D. Day, W. Chen, T. Siu, L. L. Hansen et al., Tumourand class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review, Ann Oncol, vol.28, pp.2377-85, 2017.

T. Fujii, R. R. Colen, M. A. Bilen, K. R. Hess, J. Hajjar et al., Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience, Invest New Drugs, vol.36, pp.638-684, 2018.

M. H. Geukes-foppen, E. A. Rozeman, S. Van-wilpe, C. Postma, P. Snaebjornsson et al., Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management, ESMO Open, vol.3, 2018.

J. D. Wolchok, A. Hoos, S. O'day, J. S. Weber, O. Hamid et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7432, 2009.

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti

, Clin Cancer Res, vol.23, pp.1920-1928, 2017.

E. Saada-bouzid, C. Defaucheux, A. Karabajakian, V. P. Coloma, V. Servois et al., Hyperprogression during anti-PD-1/ PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.28, pp.1605-1616, 2017.

R. L. Ferris, G. Blumenschein, F. J. Jr, J. Guigay, A. D. Colevas et al., Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, vol.375, pp.1856-67, 2016.

F. S. Hodi, W. J. Hwu, R. Kefford, J. S. Weber, A. Daud et al., Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab, J Clin Oncol, vol.34, pp.1510-1517, 2016.

S. E. , Can an immune checkpoint inhibitor (sometimes) make things worse?, Clin Cancer Res, vol.23, pp.1879-81, 2017.

L. Seymour, J. Bogaerts, A. Perrone, R. Ford, L. H. Schwartz et al., iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, pp.143-52, 2017.

H. Young, R. Baum, U. Cremerius, K. Herholz, O. Hoekstra et al., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, vol.35, pp.1773-82, 1999.

C. Sachpekidis, L. Larribere, L. Pan, U. Haberkorn, A. Dimitrakopoulou-strauss et al., Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study, Eur J Nucl Med Mol Imaging, vol.42, pp.386-96, 2015.

R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, issue.1, pp.122-50, 2009.

K. Kaira, T. Higuchi, I. Naruse, Y. Arisaka, A. Tokue et al., Metabolic activity by (18)F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC, Eur J Nucl Med Mol Imaging, vol.45, pp.56-66, 2018.

S. Y. Cho, E. J. Lipson, H. J. Im, S. P. Rowe, E. M. Gonzalez et al., Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET/CT imaging in patients with advanced melanoma, J Nucl Med, vol.58, pp.1421-1429, 2017.

H. Anwar, C. Sachpekidis, J. Winkler, A. Kopp-schneider, U. Haberkorn et al., Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab, Eur J Nucl Med Mol Imaging, vol.45, pp.376-83, 2018.

C. Sachpekidis, H. Anwar, J. Winkler, A. Kopp-schneider, L. Larribere et al., The role of interim (18)F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma, Eur J Nucl Med Mol Imaging, vol.45, pp.1289-96, 2018.

B. Y. Kong, A. M. Menzies, C. A. Saunders, E. Liniker, S. Ramanujam et al., Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy, Pigment Cell Melanoma Res, vol.29, pp.572-579, 2016.

N. Eshghi, T. F. Lundeen, and P. H. Kuo, Dynamic adaptation of tumor immune response with nivolumab demonstrated by 18F-FDG PET/CT, Clin Nucl Med, vol.43, pp.114-120, 2018.

F. Grizzi, A. Castello, and E. Lopci, Is it time to change our vision of tumor metabolism prior to immunotherapy?, Eur J Nucl Med Mol Imaging, vol.45, pp.1072-1077, 2018.

M. Higuchi, Y. Owada, T. Inoue, Y. Watanabe, T. Yamaura et al., FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer, World J Surg Oncol, vol.14, p.238, 2016.

D. R. Spigel, J. E. Chaft, S. Gettinger, B. H. Chao, L. Dirix et al., FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1-selected patients with non-small-cell lung cancer, J Thorac Oncol, 2018.

E. Lopci, L. Toschi, F. Grizzi, D. Rahal, L. Olivari et al., Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery, Eur J Nucl Med Mol Imaging, vol.43, pp.1954-61, 2016.

K. Takada, G. Toyokawa, T. Okamoto, S. Baba, Y. Kozuma et al., Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography, Cancer Med, vol.6, pp.2552-61, 2017.

Z. D. Horne, R. Jack, Z. T. Gray, J. M. Siegfried, D. O. Wilson et al., Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer, J Surg Res, vol.171, pp.1-5, 2011.

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-71, 2014.

G. Mazzaschi, D. Madeddu, A. Falco, G. Bocchialini, M. Goldoni et al., Low PD-1 expression in cytotoxic CD8(+) tumorinfiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value, Clin Cancer Res, vol.24, pp.407-426, 2018.

C. M. Breki, A. Dimitrakopoulou-strauss, J. Hassel, T. Theoharis, C. Sachpekidis et al., Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab, EJNMMI Res, vol.6, p.61, 2016.

S. Rossi, L. Toschi, A. Castello, F. Grizzi, L. Mansi et al., Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors, Eur J Nucl Med Mol Imaging, vol.44, pp.2310-2335, 2017.

K. K. Tsai, M. H. Pampaloni, C. Hope, A. P. Algazi, B. M. Ljung et al., Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade, J Immunother Cancer, vol.4, p.58, 2016.

J. W. Wachsmann, R. Ganti, and F. Peng, Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT

, Acad Radiol, vol.24, pp.111-116, 2017.

C. F. Friedman, T. A. Proverbs-singh, and M. A. Postow, Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review, JAMA Oncol, vol.2, pp.1346-53, 2016.

K. Haratani, H. Hayashi, Y. Chiba, K. Kudo, K. Yonesaka et al., Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer, JAMA Oncol, vol.4, pp.374-382, 2018.

S. Chicklore, V. Goh, M. Siddique, A. Roy, P. K. Marsden et al., Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis, Eur J Nucl Med Mol Imaging, vol.40, pp.133-173, 2013.

C. Lasnon, B. Enilorac, H. Popotte, and A. N. , Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs), EJNMMI Res, vol.7, p.30, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01856125

C. Lasnon, M. Majdoub, B. Lavigne, P. Do, M. J. Visvikis et al., 18)F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer, Eur J Nucl Med Mol Imaging, vol.43, pp.2324-2359, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01386846

N. Aide, C. Lasnon, P. Veit-haibach, T. Sera, B. Sattler et al., EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies, Eur J Nucl Med Mol Imaging, vol.44, pp.17-31, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01856095